Nicholas (Nick) J. Sarlis
Brief Biosketch – August 2015
Nicholas J. Sarlis, MD, PhD, FACP is the VP & Head of Global Medical Affairs (GMA) at Incyte Corp in Wilmington, DE. Nick is an experienced clinician, with knowledge of Hem/Med Oncology, exper pharmacology, endocr neoplasia, biometrics & data analysis, sci comm, external expert networking, late clin development,
Nicholas (Nick) J. Sarlis
Brief Biosketch – August 2015
Nicholas J. Sarlis, MD, PhD, FACP is the VP & Head of Global Medical Affairs (GMA) at Incyte Corp in Wilmington, DE. Nick is an experienced clinician, with knowledge of Hem/Med Oncology, exper pharmacology, endocr neoplasia, biometrics & data analysis, sci comm, external expert networking, late clin development, HEOR, and Pharma-relevant regulations (US & EU).
Incyte Corp. is a global biopharmaceutical company focused on the discovery, development & commercialization of proprietary drugs, primarily in Oncology. Incyte is bringing important new drugs to market, which puts the company in a strong position to make a difference in the lives of patients. In his role, Nick is responsible for establishing, leading and strategically directing a multi-functional GMA team. His team's focus is on Incyte's pipeline, focusing on tumor stromal modulation (JAK1 inh), immuno-oncology (IO: epacadostat [the original IDO1 inh]; select compounds from Agenus) and modulating transcriptional regulation & cell signaling (inh's of PI3K-d, FGFR, PIM and BRD). Combinatorial approaches are strongly emphasized in Incyte's clinical development portfolio.
Nick began his pharmaceutical career with Sanofi-Aventis US, becoming Snr Med Director & managing critical parts of the medical support for S-A's Oncology franchises. Nick has had superb training in both US & UK, and pursued a 10-yr highly productive academic career at the NIH (as Snr Clin Investigator), and the MD Anderson Cancer Center (as Assoc Prof). Over the last 15 years, he has focused on clin & translational research, sci communication, and networking with peers in Cancer Medicine.
Nick is an advisor for the Glob Translat Med Consortium/ EUSTM, a reviewer for COST (Comm Européenne), & faculty at FAES, Inc. He is a member of 20+ professional societies.
He has authored 135+ publications with strong focus on cancer, and has delivered invited lectures & presentations worldwide.
Vice President; Head, Global Medical Affairs (GMA) @ As a seasoned pharmaceutical physician in this business-critical & strategy-defining position, Nick leads and is responsible for the planning and timely & on-budget execution of Global Medical Affairs (GMA) activities that provide medical and scientific support for the company's new products/ pipeline agents in Oncology. Under Nick's leadership, the Incyte GMA team plans, initiates, coordinates, manages, produces, and delivers novel medical knowledge (through non-registrational and pragmatic company-sponsored studies and a portfolio of independent-sponsored trials [ISTs]) on new products, as well as decisively ‘drives’ the principles, boundary documents, and data conceptualization and delivery platforms behind a comprehensive scientific communication plan. Nick and his team also strategically plan and implement a networking plan with top-tier international key external clinical and scientific experts.
The GMA team at Incyte is part of the Drug Development organization and works seamlessly with colleagues at Global Product Strategy & Business Development and Licensing (GPS/BD&L), Clinical Development, Regulatory Affairs, US Medical Affairs, and Discovery/ Biology.
Nick reports directly to the Chief Medical Officer (CMO) of Incyte, Dr. Steven Stein, MD. From June 2015 to Present (7 months) Vice President; Head, Medical Affairs @ Responsible for establishing and strategically directing a multi-functional team for the company's lead program (ruxolitinib; formerly known as: INCB18424; Trade name: JAKAFI), as well as other compounds.
Provision of medical brand strategy in all functional ascpects of Medical Affairs for ruxolitinib.
Collaborate extensively with the CMO, CCO, and the rest of the Executive Team (and CEO) to meet corporate brand goals for the Med Affairs Department.
Maintain and enrich top-level relationships with institutional and advocacy leaders in Oncology in the US
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily in Oncology. Incyte is bringing important new drugs to market, which puts the company in a strong position to make a difference in the lives of patients. From September 2010 to June 2015 (4 years 10 months) Senior Medical Director @ From June 2006 to September 2010 (4 years 4 months) Associate Professor @ From 2002 to 2006 (4 years) Clinical Investigator @ From 1997 to 2002 (5 years)
Fellowship (Clinical and Research), Clinical Endocrinology, Diabetes, and Metabolism @ National Institutes of Health (NIH) From 1995 to 1997 Internal Medicine Residency, Internal Medicine @ University of Utah School of Medicine From 1992 to 1995 PhD, Neuroendocrinology; Faculty of Medicine @ University of London From 1989 to 1992 Doctorate of Medicine, Experimental Pharmacology @ Ethnikon kai Kapodistriakon Panepistimion Athinon From 1988 to 1989 MBBS (equiv. to US "M.D."), Medicine @ Ethnikon kai Kapodistriakon Panepistimion Athinon From 1982 to 1988 Nicholas FACP is skilled in: Oncology, Cancer, Internal Medicine, Translational Research, Clinical Trials, Clinical Research, Pharmaceuticals, Life Sciences, Hematology, Pharmacology, Translational Medicine, medical affairs, Building Alliances, Cross-functional Team Leadership, Team Leadership
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension